0001209191-20-064574.txt : 20201218 0001209191-20-064574.hdr.sgml : 20201218 20201218202901 ACCESSION NUMBER: 0001209191-20-064574 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201216 FILED AS OF DATE: 20201218 DATE AS OF CHANGE: 20201218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zinda Michael CENTRAL INDEX KEY: 0001815366 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 201402107 MAIL ADDRESS: STREET 1: C/O REPARE THERAPEUTICS INC. STREET 2: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-16 0 0001808158 Repare Therapeutics Inc. RPTX 0001815366 Zinda Michael C/O REPARE THERAPEUTICS INC. 7210 FREDERICK-BANTING, SUITE 100 ST-LAURENT A8 H4S 2A1 QUEBEC, CANADA 0 1 0 0 EVP, Chief Science Officer Common Stock 2020-12-16 4 M 0 6876 1.637 A 92105 D Common Stock 2020-12-16 4 M 0 2080 1.637 A 94185 D Common Stock 2020-12-16 4 S 0 8022 35.17 D 86163 D Common Stock 2020-12-16 4 S 0 934 36.01 D 85229 D Common Stock 2020-12-18 4 M 0 8321 2.062 A 93550 D Common Stock 2020-12-18 4 S 0 8121 34.59 D 85429 D Common Stock 2020-12-18 4 S 0 200 35.10 D 85229 D Employee Stock Option (right to buy) 1.637 2020-12-16 4 M 0 6876 0.00 D 2027-06-14 Common Stock 6876 4122 D Employee Stock Option (right to buy) 1.637 2020-12-16 4 M 0 2080 0.00 D 2027-12-04 Common Stock 2080 29538 D Employee Stock Option (right to buy) 2.062 2020-12-18 4 M 0 8321 0.00 D 2029-03-29 Common Stock 8321 85707 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.753 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3) and (4). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.23 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.99 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.05 to $35.15 inclusive. Twenty-five percent (25%) of the shares subject to the option vested on June 14, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to the option vested on March 29, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. /s/ Steve Forte, Attorney-in-Fact 2020-12-18